Virax Biolabs’ CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy.
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
Read Our Press Release
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
Virax Biolabs Presentation from the 19th World Immune Regulation Meeting: “Evaluation of T cell dysfunction in Post Acute Infection Syndromes”
Dr. Nigel McCracken, our Chief Operating Officer, will present on “Evaluation of T cell dysfunction in Post Acute Infection Syndromes” at the 19th World Immune Regulation Meeting (WIRM) in Davos, Switzerland today (March 12th) at 8pm in Foyer A1. For those not able to join us in Davos, you can have a look at the […]
Virax Biolabs to Present at 19th World Immune Regulation Meeting
Virax Biolabs Presents at H.C. Wainwright’s 26th Annual Global Investment Conference
Dr. Ailsa Snaith Joins the Virax Biolabs Team
We’re excited to welcome Dr. Ailsa Snaith to the Virax Biolabs team today – she will be the newest member of our Advisory Board. A scientist and clinician with a deep résumé in both academic and non-academic settings, Dr. Snaith will bring years of powerful experience to help us augment our ViraxImmune™ platform. With her […]
Jeff Hurwitz and Gordon Powell Join the Virax Biolabs Team
This week, we’re pleased to be welcoming Jeff Hurwitz and Gordon Powell to the team. Their decades of experience in the in-vitro diagnostics (IVD) space will be a great addition to our growing team and will aid us as we expand into new markets. Jeff (Business Development, Americas) will be an agile lead for our […]